advertisement
Abstract #8493 Published in IGR 5-1
A randomised, double masked, multicentre clinical trial comparing bimatoprost and timolol for the treatment of glaucoma and ocular hypertension
Whitcup SM; Cantor LB; VanDenburgh AM; Chen KBritish Journal of Ophthalmology 2003; 87: 57-62
AIM: To evaluate the safety and efficacy of bimatoprost 0.03% once daily or twice daily compared with timolol 0.5% twice daily in patients with glaucoma or ocular hypertension. METHODS: Multicenter, double masked, randomized, parallel group, three-month trial comparing bimatoprost once daily (n = 240), bimatoprost twice daily (n = 240), and timolol twice daily (n = 122). The primary efficacy end point was diurnal intraocular pressure (IOP) (8 a.m., 10 a.m., 4 p.m.). Safety measures included adverse events, ocular parameters, and systemic variables. RESULTS: Bimatoprost once daily provided significantly lower mean IOP than timolol twice daily at all times and follow up visits (p < 0.001). At month 3, mean IOP reductions from baseline at 10 a.m. (peak timolol effect) were bimatoprost once daily, 8.0 mmHg (32.4%); bimatoprost twice daily, 6.3 mmHg (25.2%); timolol, 5.5 mmHg (22.7%). Bimatoprost twice daily was also more effective than timolol, but was not as effective as bimatoprost once daily. A higher percentage of patients achieved low target pressures with bimatoprost once daily than with timolol. The most frequent side-effects with bimatoprost were eyelash growth and mild conjunctival hyperemia. Systemic safety parameters were not affected by bimatoprost. CONCLUSIONS: Bimatoprost 0.03% once daily demonstrated superior efficacy compared with timolol 0.5% twice daily in patients with elevated IOP. Bimatoprost once daily was more effective than twice daily dosing.
Dr. S.M. Whitcup, Allergan, Inc, Irvine, CA, USA. Whitcup_Scott@allergan.com
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
